Component

New keratinocyte skin cancer incidence

New keratinocyte skin cancer incidence. The model and exposure of each linked claim define its scope.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. During ONTRAC treatment, new nonmelanoma skin cancers were 23% lower with nicotinamide than placebo (95% CI 4–38%); there was no evidence of benefit after discontinuation.

    Nicotinamide → New keratinocyte skin cancer incidence source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    Niacin precursor form and the measured endpoint are separate graph entities.
    evidence_span
    {"source_cache": "artifacts/niacin-clinical-sources/chen2015.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "7a305aa1d363f375f8cb640b5ddc5f77517f0229a6041558e392d7a07e198aa8", "start_char": 0, "end_char": 2368, "text_sha256": "7a305aa1d363f375f8cb640b5ddc5f77517f0229a6041558e392d7a07e198aa8"}
    experimental_model
    ONTRAC double-blind randomized trial; 386 high-risk participants with at least two recent nonmelanoma skin cancers
    exposure
    Nicotinamide 500 mg twice daily for 12 months; observation for a further six months
    limitations
    Selected high-risk population; this is pharmacological prevention, not proof of deficiency. Combined endpoint differs from subtype effects. Results do not establish efficacy in every population or after treatment stops.
    nutrient_topic
    Niacin research collection; topical membership is not evidence of a direct dietary effect. · Niacin (vitamin B3)
    organism
    Homo sapiens
    plain_language
    Nicotinamide reduced new skin cancers during treatment in this selected high-risk group; protection was not shown to persist after stopping.
    primary_references
    [nia-clin-chen2015] A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. (2015). https://pubmed.ncbi.nlm.nih.gov/26488693/ DOI: 10.1056/nejmoa1506197
    tissue_or_cell_type
    Skin cancer counts

    Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17) · lines 1431–1443

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · ONTRAC double-blind randomized trial; 386 high-risk participants with at least two recent nonmelanoma skin cancers · source_derived_draft · unverified_draft

    ### nia-clin-ontrac-skin During ONTRAC treatment, new nonmelanoma skin cancers were 23% lower with nicotinamide than placebo (95% CI 4–38%); there was no evidence of benefit after discontinuation. Condition category: normal nutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Nicotinamide reduced new skin cancers during treatment in this selected high-risk group; protection was not shown to persist after stopping. organism: Homo sapiens tissue_or_cell_type: Skin cancer counts experimental_model: ONTRAC double-blind randomized trial; 386 high-risk participants with at least two recent nonmelanoma skin cancers limitations: Selected high-risk population; this is pharmacological prevention, not proof of deficiency. Combined endpoint differs from subtype effects. Results do not establish efficacy in every population or after treatment stops. exposure: Nicotinamide 500 mg twice daily for 12 months; observation for a further six months cross_nutrient: Niacin precursor form and the measured endpoint are separate graph entities. evidence_span: {"source_cache": "artifacts/niacin-clinical-sources/chen2015.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "7a305aa1d363f375f8cb640b5ddc5f77517f0229a6041558e392d7a07e198aa8", "start_char": 0, "end_char": 2368, "text_sha256": "7a305aa1d363f375f8cb640b5ddc5f77517f0229a6041558e392d7a07e198aa8"} [nia-clin-chen2015] A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. (2015). https://pubmed.ncbi.nlm.nih.gov/26488693/ DOI: 10.1056/nejmoa1506197
    Complete structured claim and evidence

  2. ONTRANS recorded 207 versus 210 new keratinocyte cancers with nicotinamide and placebo: rate ratio 1.0, 95% CI 0.8–1.3.

    Nicotinamide → New keratinocyte skin cancer incidence source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    Niacin precursor form and the measured endpoint are separate graph entities.
    evidence_span
    {"source_cache": "artifacts/niacin-clinical-sources/allen2023.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "0331a413552524d52730cd68ea35a70b589a37aa0a29d25bbc7b6f4777dbdcbd", "start_char": 0, "end_char": 2229, "text_sha256": "0331a413552524d52730cd68ea35a70b589a37aa0a29d25bbc7b6f4777dbdcbd"}
    experimental_model
    ONTRANS double-blind randomized trial; 158 solid-organ transplant recipients with recurrent keratinocyte cancers
    exposure
    Nicotinamide 500 mg twice daily versus placebo for 12 months
    limitations
    Trial stopped early because of poor recruitment. Population differs materially from immunocompetent ONTRAC participants; neither the population difference nor different statistical results alone constitutes a research contradiction.
    nutrient_topic
    Niacin research collection; topical membership is not evidence of a direct dietary effect. · Niacin (vitamin B3)
    organism
    Homo sapiens
    plain_language
    The same daily amount did not show a skin-cancer reduction in this smaller transplant-recipient trial.
    primary_references
    [nia-clin-allen2023] Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. (2023). https://pubmed.ncbi.nlm.nih.gov/36856616/ DOI: 10.1056/nejmoa2203086
    tissue_or_cell_type
    Skin cancer counts

    Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17) · lines 1445–1457

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · ONTRANS double-blind randomized trial; 158 solid-organ transplant recipients with recurrent keratinocyte cancers · source_derived_draft · unverified_draft

    ### nia-clin-ontrans-skin ONTRANS recorded 207 versus 210 new keratinocyte cancers with nicotinamide and placebo: rate ratio 1.0, 95% CI 0.8–1.3. Condition category: normal nutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The same daily amount did not show a skin-cancer reduction in this smaller transplant-recipient trial. organism: Homo sapiens tissue_or_cell_type: Skin cancer counts experimental_model: ONTRANS double-blind randomized trial; 158 solid-organ transplant recipients with recurrent keratinocyte cancers limitations: Trial stopped early because of poor recruitment. Population differs materially from immunocompetent ONTRAC participants; neither the population difference nor different statistical results alone constitutes a research contradiction. exposure: Nicotinamide 500 mg twice daily versus placebo for 12 months cross_nutrient: Niacin precursor form and the measured endpoint are separate graph entities. evidence_span: {"source_cache": "artifacts/niacin-clinical-sources/allen2023.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "0331a413552524d52730cd68ea35a70b589a37aa0a29d25bbc7b6f4777dbdcbd", "start_char": 0, "end_char": 2229, "text_sha256": "0331a413552524d52730cd68ea35a70b589a37aa0a29d25bbc7b6f4777dbdcbd"} [nia-clin-allen2023] Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. (2023). https://pubmed.ncbi.nlm.nih.gov/36856616/ DOI: 10.1056/nejmoa2203086
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards